Medicare’s GLP-1 Bridge Program: An Overview

Starting in July, certain Medicare beneficiaries will be able to access GLP-1 medications for a fixed monthly rate. This temporary program is planned to run until the end of 2027. However, questions remain about its implementation details, even as the launch approaches.

The Medicare GLP-1 Bridge, described as a ‘time-limited demonstration’ by the Centers for Medicare and Medicaid Services (CMS), will span from July 1, 2026, to December 31, 2027. Announced in December, this initiative allows eligible Medicare Part D enrollees to obtain GLP-1 medications for a $50 monthly copay. Although GLP-1 drugs treat diabetes, obesity, and some heart conditions, the Bridge program will focus primarily on weight management solutions for beneficiaries without a covered medical condition under Part D.

Current federal law prohibits Medicare from covering weight loss medications. Despite this, programs like the Obesity Care Advocacy Network (OCAN) have endorsed the initiative. OCAN Coordinator Cristy Gallagher called this a ‘historic milestone’ in combating the obesity epidemic. Some regulatory observers, nonetheless, express concerns over program administration, and questions persist about its costs. Bob Herman of Stat News noted that inquiries about the program’s cost have gone unanswered. The Hill also reached out to the Department of Health and Human Services for cost-related information.

How it Works

According to CMS, Medicare enrollees need not complete additional paperwork beyond obtaining a prescription from their doctor. A medical provider must submit a prior authorization request alongside a prescription for eligible GLP-1 medications. Covered medications include Wegovy, Zepbound, and Foundayo. If patients switch medications mid-program, a new prior authorization form is required.

Pharmacists will forward prescriptions to the Bridge program’s central processor, known as the Bridge PCN. Aurelia Chaudhury, co-lead of CMS’s Cell and Gene Therapy Access Model, clarified in a webinar that prospective prior authorizations at the time of prescribing will not be processed.

The prior authorization form will require physicians to confirm that their patients do not have Type 2 diabetes, moderate to severe obstructive sleep apnea, or MASH fatty liver disease. Claims won’t be processed before July 1. Kelly Strachan, a CMS health insurance specialist, mentioned that the Bridge program aims to test the benefits of providing GLP-1 products at a uniform CMS-negotiated price to improve outcomes and reduce long-term spending. The $50 monthly copay will not contribute to a patient’s deductible or maximum out-of-pocket expenses.

When questioned about plans for the program post-2027, Chaudhury said there is significant patient interest in knowing what happens beyond December 31, 2027, and that CMS will provide more information soon.

Who is Eligible

Beneficiaries need to be enrolled in either a standalone prescription drug plan or a Medicare Advantage coordinated care plan. Special Needs Plan enrollees, those in employer/union group waiver plans, and the Limited Income Newly Eligible Transition program are eligible. Tricare For Life beneficiaries must also be enrolled in a qualifying Part D plan type to access the Bridge program.

Catherine Varney from the Obesity Medicine Association highlighted, in the webinar, that the ideal beneficiaries of the GLP-1 Bridge are those at high risk of obesity-related diseases. Obesity is linked to over 200 chronic conditions, including 13 cancer types. Eligibility is based on body mass index (BMI), with specific conditions required for different BMI ranges. Participants must have a BMI of 27 or higher and meet certain health criteria. Those with a BMI of 35 or greater do not require an additional qualifying diagnosis.

Regulatory Concerns

The Bridge program operates outside typical Medicare rules, which do not cover weight loss-specific medications. Some worry about potential fraud risks, as telehealth visits may meet the requirements for a Bridge program prescription. Christopher Frisina, a regulatory counsel, flagged possible incentives for new or existing telehealth providers to engage in the Medicare space. CMS appears to have set strong checks, requiring providers to submit detailed forms before approval. However, this does not eliminate fraud risks entirely.

While CMS hasn’t disclosed specific cost estimates or enrolment projections, it states that the program will not follow the standard Part D cost-sharing structure, operating outside typical coverage and payment pathways.